Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Most recent entries » Horizons in World Cardiovascular Research. Volume 2 Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Explosives Detection Canines and Homeland Security: Background and Analyses
$62.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Beneficial Clinical Effects of Perhexiline in Cardiac Patients: Multiple Biochemical Mechanisms, pp. 1-27
Tell A Friend
 
Tell someone you know about this product.
Beneficial Clinical Effects of Perhexiline in Cardiac Patients: Multiple Biochemical Mechanisms, pp. 1-27 $100.00
Authors:  (Yuliy Y. Chirkov, Aaron L. Sverdlov, John D. Horowitz, Basil Hetzel Institute, The Queen Elizabeth Hospital/Dept. of Medicine, The University of Adelaide, Australia)
Abstract:
Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline's reintroduction into clinical practice. Recent clinical data have proved its safety and
maintained efficacy. Perhexiline reduced anginal frequency in patients with refractory angina. In patients with chronic heart failure, perhexiline improved peak exercise oxygen consumption, left ventricular ejection fraction, symptoms, resting and peak stress
myocardial function. Perhexiline also appears to be effective in suppressing symptoms in patients with acute coronary syndromes or with advanced and inoperable aortic valvular stenosis. Herein we discuss perhexiline's pharmacology with particular emphasis on its
mechanism(s) of action. 


Available Options:
Version:
Special Focus Titles
01.The European Union and the Global Financial Crisis: A View from 2016
02.International Human Rights and Justice
03.The Dutch: Creativity in the Face of Nature
04.Freshwater Resources of the Tropical North of Australia: A Hydrobiological Perspective
05.International Perspectives on Traumatic Stress: Theory, Access, and Mental Health Services
06.Marine Benthos: Biology, Ecosystem Functions and Environmental Impact
07.Mental Health Conditions and Services in Selected African Countries: Implications for Social Work and Human Services Professions
08.Child Maltreatment: Emerging Issues in Practice, Care and Prevention
09.Creativity in Gifted Children
10.Higher Education in Hong Kong: Nurturing Students to be Caring Service Leaders
11.Moral Classroom Management in Early Childhood Education
12.The Silver Conclave: Heroes, Heroines and Villains of English Literature

Nova Science Publishers
© Copyright 2004 - 2016

Beneficial Clinical Effects of Perhexiline in Cardiac Patients: Multiple Biochemical Mechanisms, pp. 1-27